Finance

Lists
Q3 2026 earnings • in 3 days
See details
IPN:EPA
Ipsen SA
€148.40
-0.40%
(-0.60) 1D
Oct 19, 5:35:18 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for IPN...
Open
€150.20
High
€150.20
Low
€146.90
Mkt. cap
12.64B
Avg. vol.
106.72K
Volume
83.11K
P/E ratio
24.03
52-wk high
€174.00
52-wk low
€112.70
EPS
€6.18
Shares outstanding
83.81M
No. of employees
6K
Open
€150.20
High
€150.20
Low
€146.90
Mkt. cap
12.64B
Avg. vol.
106.72K
Volume
83.11K
P/E ratio
24.03
52-wk high
€174.00
52-wk low
€112.70
EPS
€6.18
Shares outstanding
83.81M
No. of employees
6K
News stories
From web sources and news partners
Profile
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales. Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
About Ipsen SA
CEODavid Loew
Employees5.54K
Founded1929
Headquarters-
SectorPharmaceutical industry
Websiteipsen.com
Next call in 3 days
Thu, Oct 22, 1:00 PM
Fiscal period
Q3 2026
- / -
Revenue / Est. (EUR)
- / 1.12B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
996.05M
996.05M
1.15B
1.15B
Cost of goods sold
212.90M
212.90M
217.60M
217.60M
Cost of revenue
212.90M
212.90M
217.60M
217.60M
Research and development expenses
194.55M
194.55M
201.25M
201.25M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
278.60M
278.60M
304.15M
304.15M
Operating expense
523.20M
523.20M
604.50M
604.50M
Total operating expenses
736.10M
736.10M
822.10M
822.10M
Operating income
259.95M
259.95M
327.50M
327.50M
Other non operating income
-7.35M
-7.35M
-6.50M
-6.50M
EBT including unusual items
76.55M
76.55M
273.85M
273.85M
EBT excluding unusual items
248.45M
248.45M
316.50M
316.50M
Income tax expense
22.05M
22.05M
72.55M
72.55M
Effective tax rate
28.80%
28.80%
26.49%
26.49%
Other operating expenses
50.05M
50.05M
99.10M
99.10M
Net income
54.75M
54.75M
201.55M
201.55M
Net profit margin
5.50%
5.50%
17.53%
17.53%
Earnings per share
-
-
-
-
Interest and investment income
8.25M
8.25M
8.80M
8.80M
Interest expense
-10.20M
-10.20M
-10.45M
-10.45M
Net interest expenses
-1.95M
-1.95M
-1.65M
-1.65M
Depreciation and amortization charges
-
-
-
-
EBITDA
331.25M
331.25M
401.65M
401.65M
Gain or loss from assets sale
9.75M
9.75M
900.00K
900.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps